Company intelligence / Profile preview

ViraTherapeutics

Rum, Tyrol, Austria

Ownership: Private
Employees: ~35
Development stage: Other

Overview

ViraTherapeutics is developing VSV-GP, a pseudotyped vesicular stomatitis virus engineered as an oncolytic cancer immunotherapy; published and company materials describe ongoing preclinical safety and efficacy work with plans for first-in-human oncology trials, but no completed clinical trial results are publicly reported yet.[1][2][3]

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyGene therapyBiologic
Industry: Biotech

Partnerships

Boehringer Ingelheim (strategic collaboration and subsequent acquisition focusing on next-generation oncolytic viral-based cancer immunotherapies)[2][4]

Beyond the preview

Go deeper on ViraTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViraTherapeutics.

Explore the full profile